TICKERNERD
Menu
MTNBMTNBHealthcare · Biotechnology

MTNB Stock Forecast: Matinas BioPharma Holdings, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$0.16
−1.60% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 19 Sept 2026 — in the lower half.

Market cap
$2.4M
Ticker Nerd rank
44 / 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$1.6M
Net income−$1.3M
Free cash flow−$1.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.3%
1M
−21.4%
YTD
−72.6%
1Y
−90.7%
From 52W high
−92.2%
From 52W low
+0.2%
$0.16
$2.06
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MTNB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Matinas BioPharma Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
44 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
99
Accruals
85
Issuance
73
Growth
64
Quality
28
Volatility
28
Value
25
Revisions
25
Momentum
22

Size (99): Smaller than most of the companies we track.

Momentum (22): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MTNB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MTNB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$0.50$1.00$1.50$2.00Oct 25Jan 26Apr 26Jul 26MTNB

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Oct 2024Maxim GroupDowngradeHold—
11 Oct 2023BTIGReinstatesBuy$3.00
31 Jan 2023HC Wainwright & Co.ReiteratesBuy—
13 Aug 2020Aegis CapitalMaintainsBuy—
27 Jan 2020Piper SandlerInitiatesOverweight—
24 Jan 2020SunTrust Robinson HumphreyInitiatesBuy—
26 June 2019H.C. WainwrightInitiatesBuy—
26 June 2019HC Wainwright & Co.InitiatesBuy—
17 May 2019BTIGInitiatesBuy—
17 May 2019BTIG ResearchInitiatesBuy—
11 Feb 2019Roth CapitalInitiatesBuy—
13 Nov 2018Maxim GroupMaintainsBuy—
13 Aug 2018Maxim GroupMaintainsBuy—
10 July 2018Maxim GroupMaintainsBuy—
1 Nov 2016Aegis CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MTNB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MTNB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Matinas BioPharma Holdings, Inc. returned −90.7% against +16.3% for the S&P 500, dividends included.

MTNB vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26MTNBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MTNB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Matinas BioPharma Holdings, Inc. (MTNB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
—
Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
−0.2×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−141.2%

Higher than 10% of US stocks

Return on assets
−56.2%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Matinas BioPharma Holdings, Inc. (MTNB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Matinas BioPharma Holdings, Inc. has a market value of $2.4M and an enterprise value of $1.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$6.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$6.4M.

  • Shares outstanding: 6.4M.

  • Trailing P/E: −0.1×; forward P/E: −0.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Matinas BioPharma Holdings, Inc. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

MTNB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MTNBMatinas BioPharma Holdings, Inc.$2.4M
44
CDTCDT Equity, Inc.$2.4M
11
SLXNSilexion Therapeutics Corp.$2.4M
53
SPRCSciSparc Ltd.$2.6M
19
ARTLArtelo Biosciences, Inc.$2.2M
15
PPCBPropanc Biopharma, Inc.$2.1M
40
CRISCuris, Inc.$2.1M
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Matinas BioPharma Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MTNB news & analysis

GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output

GlobeNewsWire · 14 Sept 2026neutral

GH Power has signed a multi-year hydrogen offtake agreement with Change Energy for output from its Hamilton facility. The deal marks GH Power's first commercial hydrogen offtake and validates hydrogen production from its proprietary aluminum-water reactor platform.

Why it matters — The item concerns GH Power, not Matinas BioPharma, so a MTNB watcher would only care insofar as it relates to a possibly affiliated or otherwise relevant company.

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

GlobeNewsWire · 4 Sept 2026negative

Matinas BioPharma announced that on August 31, 2026 it received a notice from NYSE American stating that the Company is not in compliance with continued listing standards under Section 1003(a)(i) of the Company Guide, which requires stockholders' equity of at least $2.0 million for companies reporting losses in two of the three most recent fiscal years.

Why it matters — A NYSE American non-compliance notice related to the Company's stockholders' equity could affect MTNB's listing status, so shareholders would want to monitor any resulting steps or consequences.

FAQ

Frequently asked questions about MTNB stock

Is MTNB stock a buy right now?

Of the 1 analysts covering Matinas BioPharma Holdings, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Matinas BioPharma Holdings, Inc. 44 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MTNB?

As at 19 Sept 2026, Matinas BioPharma Holdings, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the MTNB stock forecast for 2030?

No analyst covering Matinas BioPharma Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MTNB are extrapolating price history, which says nothing about the business.

How has MTNB stock performed over the past year?

Matinas BioPharma Holdings, Inc. returned -90.7% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Matinas BioPharma Holdings, Inc. do?

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing pharmaceutical products using its lipid nanocrystal (LNC) delivery technology.

What is the latest news on MTNB?

The most recent item we track (GlobeNewsWire, 14 Sept 2026): "GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output". GH Power has signed a multi-year hydrogen offtake agreement with Change Energy for output from its Hamilton facility. The deal marks GH Power's first commercial hydrogen offtake and validates hydrogen production from its proprietary aluminum-water reactor platform.

Company

About Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing pharmaceutical products using its lipid nanocrystal (LNC) delivery technology. The company’s platform is designed to support the delivery of a range of therapeutic modalities, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its current work has centered on anti-infective applications, including MAT2203, an oral formulation of amphotericin B, alongside additional discovery programs in oncology and inflammation. Matinas BioPharma Holdings, Inc. operates from Bedminster, New Jersey and remains positioned as a developer of novel drug-delivery solutions within the healthcare and biotechnology market.

CEO Mr. Jerome D. Jabbour J.D. · 2 employees · United States · https://www.matinasbiopharma.com